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Abstract: Two types of iron oxide nanoparticles were synthesized by 
coprecipitation of Fe(II) and Fe(III) chlorides: water-dispersible γ-Fe2O3 and organic 
solvent-dispersible oleic acid-coated Fe3O4 particles. The nanoparticles, together 
with human serum albumin (HSA) serving as a model for a protein-type drug, were 
then incorporated in poly(lactide-co-glycolide) (PLGA) particles using double 
emulsion solvent evaporation technique. Morphology, size and particle size 
distribution of the resulting particles was analyzed by electron microscopy and 
dynamic light scattering. Iron oxide and HSA encapsulating efficiency was 
determined by Prussian Blue staining and micro-BCA assay, respectively.  
 
Introduction  
Nanobiotechnologies are promising tools in biomedical and pharmaceutical sciences, 
in particular in controlled drug delivery systems and diagnostics. In the former, the 
nanoparticle-based systems offer three major advantages: (i) targeting of specific 
organs in the body, (ii) achieving an effective drug concentration in the target and (iii) 
minimizing undesirable side effects at non-target sites (Zhang et al. [1]). In the latter, 
the ability to recognize, label and image specific target cells is very important. 
Various nanoparticles, that have to be biocompatible and biodegradable, are 
designed for these purposes (De Jong et al. [2], Shao et al. [3]). 
Poly(D,L-lactic-co-glycolide) (PLGA) is a biocompatible (non-toxic) and 
biodegradable material that is FDA approved and often used for preparation of nano- 
and microparticles (Kona et al. [4], Galeska et al. [5]). Moreover, it has excellent 
drug-loading capacity. It is a great advantage that drugs that are encapsulated inside 
the polymer nanoparticles or nanocapsules can be efficiently protected against 
enzymatic and hydrolytic degradation. Moreover, if the particles contain magnetic 
core, they can be manipulated by magnetic field or monitored by magnetic resonance 
imaging. For example, anionic magnetic nanoparticles have been used to adsorb and 
release cationic drugs for potential cancer immunotherapy (Mejías et al. [6]).  
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Magnetic nanoparticles are often based on iron oxides, such as magnetite (Fe3O4) or 
maghemite (γ-Fe2O3). Both of them are nontoxic and FDA-approved for clinical use. 
Although other metals (or its oxides), such as cobalt and nickel, are highly magnetic 
materials compared to iron oxides, they are toxic. While Fe3O4 has generally better 
magnetic properties than γ-Fe2O3, the latter is less susceptible to oxidation than the 
former. If oxidation of magnetic nanoparticles occurs inside the body, highly reactive 
hydroxyl radicals will be formed which can cause serious health risks.  
Encapsulation of low- and high-molecular-weight molecules (drugs) by a polymer can 
be achieved by several methods such as micro/nanoemulsion (Lee at al. [7], Wang et 
al. [8], Urban et al. [9]), nanoprecipitation (Staunmesse at al. [10], Cheng at al. [11]), 
micelle formation (Kim at al. [12], Lu at al. [13], Talelli at al. [14]), emulsion 
polymerization (Ramírez et al. [15], Wormuth [16], Pollert et al. [17]) or solvent 
extraction/evaporation method (Feczkó at al. [18]). For instance, magnetic 
nanoparticle-embedded poly(lactide-co-glycolide) matrices were prepared as a dual 
drug-delivery and imaging system capable of encapsulating both hydrophilic 
(carboplatin) and hydrophobic (paclitaxel and rapamycin) drugs (Singh at al. [19]). 
Double emulsion combined with a solvent evaporation technique was often used for 
preparation of microspheres both in batch (Rosca et al. [20]) and microfluidic 
arrangement (Lee et al. [21]). Preparation of nanoparticles was also investigated but 
resulting particles typically had irregular shape (Fonte et al. [22], Zambaux et al. [23]). 
In the double emulsion solvent evaporation process, a primary emulsion (w/o) was 
formed by emulsifying the drug in an aqueous solution with a continuous organic 
phase containing a polymer and a solvent with low boiling point, usually 
dichloromethane or ethyl acetate. The primary emulsion was then mixed in an 
aqueous solution containing surfactant to produce a double emulsion (w/o/w) (Meng 
et al. [24], Jeffery et al. [25]). Microspheres were formed during solvent removal. The 
method was used for encapsulation of a wide range of proteins since it allowed 
hydrophilic proteins to be dissolved in aqueous phase. However, there was always a 
danger that activity of proteins could be changed by contact with the organic interface 
(Sah [26]). The double emulsion solvent evaporation technique was also examined to 
produce magnetic particles (Ngaboni Okassa et al. [27]). In this method, an aqueous 
suspension of Fe3O4 was emulsified in an organic solvent containing a preformed 
polymer. Aggregation of Fe3O4 particles made it difficult to prepare individual 
magnetic polymer particles (Gomez-Lopera et al. [28]). Moreover, the polymer shell 
was usually heterogeneous or the Fe3O4 was not completely covered by the polymer. 
Although there are many reports on preparation of PLGA micro- and nanoparticles 
for different drug depot systems (Jain [29], Péan et al. [30], Hans et al. [31], Yang et 
al. [32]), only few reports on drug-loaded magnetic PLGA particles were published 
(Akbarzadeh at al. [33], Zhou at al. [34], Andhariya at al. [35]).  
Aim of this report was to prepare human serum albumin (HSA)-loaded magnetic 
PLGA particles in submicrometer size using double emulsion solvent evaporation 
method. HSA, the most abundant plasma protein in the human body, served as a 
model for a protein-type drug. Such magnetic PLGA particles with protein-type drug 
depots should combine the advantage of biodegradability of the carrier with its easy 
handling by a magnetic field. 
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Results and discussion  
 
Iron oxide nanoparticles  
Iron oxides, such as magnetite (Fe3O4) and maghemite ( -Fe2O3), have advantage 
that they are currently the only accepted nontoxic magnetic materials for biomedical 
applications. Many methods producing superparamagnetic iron oxide nanoparticles 
have been already described (Nymfeo et al. [41], Sun et al. [42]). In this report, 
precipitation approach in water has been selected since it provides magnetic 
nanoparticles from readily available chemicals in a single step. Two types of 
magnetic nanoparticles were prepared: those dispersible in water and in organic 
media.  
First type of magnetic nanoparticles dispersible in water included the iron oxide that 
was synthesized at room temperature in air by coprecipitation in water of ferrous and 
ferric chloride with NH4OH by modification of previously reported method (Massart 
[37]). The mole ratio of Fe(II) to Fe(III) had to be close to 1/2. On addition of NH4OH, 
the initially clear yellow solution immediately turned black, indicating the precipitation 
of Fe3O4 nanoparticles. To ensure oxidation stability of the nanoparticles, Fe3O4 was 
oxidized with NaClO solution to γ-Fe2O3 that is more stable against oxidation than 
Fe3O4. To obtain a stable colloidal solution of magnetic nanoparticles (ferrofluid), 
repulsive interactions preventing aggregation were provided by citrate ions on the 
particle surface. Careful washing, which removed all low-molecular-weight products 
(salts), peptized the precipitate under the formation of colloid. Figure 1 a shows TEM 
image of dry γ-Fe2O3 nanoparticles, shape of which resembled to spheres. The 
average nanoparticle size, 11 nm, with polydispersity index PDI = 1.20, was 
determined by averaging the diameters of hundreds of particles. As expected, 
hydrodynamic size of the γ-Fe2O3 particles in water was much larger (Dh = 105 nm; 
polydispersity PI = 0.19) due to the fact that the particle doublets, triplets and 
aggregates were measured in water. Moreover, while microscopic methods 
determined number-average size of dry particles, dynamic light scattering calculated 
z-average of particles in water which was very sensitive to large objects. Both PDI 
and PI values thus suggested that even the monodisperse nanoparticles were not 
obtained, the particle size distribution was not extremely broad. 
 
 
a                                                              b 
 
Fig. 1. TEM micrographs of (a) citrate-stabilized γ-Fe2O3 nanoparticles dried from 
water and (b) oleic acid-coated Fe3O4 nanoparticles dried from dichloromethane.  
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Second type of magnetic nanoparticles involved a ferrofluid based on organic media. 
Here, ferrous and ferric salts were reduced by ammonia under nitrogen atmosphere 
to prevent oxidation of resulting Fe3O4. Oleic acid, that possesses carboxyl group 
readily adhering to the surface of an iron oxide nanoparticle, was at 90 °C used as a 
coating to ensure colloidal stability (preventing aggregation) of the particles in an 
organic medium (DCM). The stability was achieved by the long alkyl chains of oleic 
acids that float in the organic medium. In order to transfer primary Fe3O4 particles 
from aqueous to the DCM medium, they were first peptized yielding an asphalt-like 
paste from which water was easily removed. The paste, free of water, was then 
ultrasonically dispersed in DCM forming a colloid. The good dispersibility of oleic 
acid-coated Fe3O4 nanoparticles in nonpolar solvents was a result of their 
hydrophobization. Morphology, size and particle size distribution of the synthesized 
nanoparticles were again analyzed by TEM (Figure 1 b). The particles did not have 
strictly regular spherical shape, their size was 10 ± 5 nm, i.e., they were not 
monodisperse but the particle size distribution was not too broad (PDI = 1.29). 
Hydrodynamic size of oleic acid-coated Fe3O4 was measured in DCM reaching Dh = 
365 nm due to the particle aggregation; polydispersity was therefore rather high (PI = 
0.39).  
 
HSA-loaded magnetic PLGA particles  
The magnetic PLGA particles were prepared by the double emulsion solvent 
evaporation method in the presence of both HSA and iron oxide colloids. The method 
was chosen due to its simplicity and easy processing. It has other advantages like 
the particle size can be controlled by changing reaction parameters, purity of the 
particles is satisfactory and encapsulation efficiency high.  
The first approach consisted in the addition of the inner aqueous phase containing 
HSA to the oleic acid-coated Fe3O4 in DCM containing PLGA to form w/o emulsion. 
The system was then emulsified in the outer aqueous phase with dissolved PVA to 
get w/o/w emulsion. Figure 2 a, b shows SEM and TEM micrographs of HSA-loaded 
magnetic PLGA particles containing 1 wt.% oleic acid-coated Fe3O4 (relative to 
PLGA). The product consisted of majority of particles with Dn = 159 nm (PDI = 1.16) 
and a small family of large polydisperse particles (Dn = 356 nm and PDI = 1.76) 
which were obviously aggregates of small particles (Figure 2 a). The particle size 
was also measured by DLS in water according to which Dh = 213 nm and PI = 0.05. 
The size distribution found by DLS was unimodal; the reason may be that the 
measured dispersion contained the emulsifier, which was removed by washing 
before the SEM analysis, where some aggregates were observed. In order to get a 
better contrast compared to SEM image and to confirm encapsulation of Fe3O4 in the 
polymer, HSA-loaded magnetic PLGA particles were viewed also by TEM (Figure 2 
b). Figure 2 b shows that aggregates of oleic acid-coated Fe3O4 nanoparticles were 
dispersed inside a PLGA particle.  
In the second method, the inner aqueous phase contained both water-based citrate-
stabilized γ-Fe2O3 nanoparticles and HSA. This phase was added to a solution of 
PLGA in DCM to prepare the first emulsion that was then mixed in aqueous PVA 
solution to get the double emulsion. The resulting HSA-loaded magnetic PLGA 
particles, although not strictly spherical, were smaller in size than those obtained by 
the first approach. Mean size was 85 nm and the particles had a tendency to 
aggregation in dry state as documented by PDI = 1.4 (Figure 2 c). TEM image 
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confirmed that a PLGA particle contained inhomogeneously dispersed γ-Fe2O3 
nanoparticle aggregates (Figure 2 d).  
 
 
a                                                                b 
 
c                                                                d 
 
Fig. 2. SEM (a, c) and TEM (b, d) micrographs of HSA-loaded submicrometer 
magnetic PLGA particles. 1 wt.% of (a, b) oleic acid-coated Fe3O4 or (c, d) citrate-
stabilized γ-Fe2O3 relative to PLGA.  
 
In terms of HSA and iron oxide encapsulation efficiency, both methods of the iron 
oxide preparation were considered: (i) aqueous citrate-stabilized γ-Fe2O3 colloid and 
(ii) oleic acid-coated Fe3O4 nanoparticles dispersed in organic medium. HSA 
encapsulation efficiency was sufficiently high for both types of magnetic PLGA 
particles prepared from two different iron oxide types, that is, it was found to be 
89.2 % for (i) and 87.6 % for (ii). The encapsulation efficiencies of iron oxide were 
also high, i.e., 92.0 % for (i) and 99.6 % for (ii), respectively.  
 
Conclusions  
In this report, two kinds of iron oxide nanoparticles were synthesized: oleic acid-
coated Fe3O4 in DCM and citrate-stabilized γ-Fe2O3 in water. The oleic acid adsorbed 
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on the surfaces of Fe3O4 particles because of the complexation of carboxyl groups 
with iron ions. The long alkyls of oleic acid not only stabilized the Fe3O4 
nanoparticles, preventing their coagulation, but also enhanced the affinity of the 
Fe3O4 nanoparticles to the hydrophobic PLGA in the subsequent double emulsion 
solvent evaporation process. On the other hand, γ-Fe2O3 nanoparticles were 
electrostatically stabilized in water due to the citrate present on the particle surface.  
In the next step, both types of iron oxide nanoparticles together with a model protein 
drug (HSA) were encapsulated in PLGA particles using the double emulsion solvent 
evaporation method. While aqueous γ-Fe2O3 colloid was added in the primary water 
phase of the system, oleic acid-coated Fe3O4 was present in the oil (DCM) phase. 
The resulting HSA-loaded magnetic PLGA particles had submicrometer size and they 
were relatively stable in aqueous media. Avoidance of particle aggregation is 
important in terms of designing injection drug formulations and allowing sterilization 
by ultra-filtration. Moreover, such particles could provide a dual drug-delivery and 
imaging system using magnetic force to target the drug-loaded vehicles to a specific 
organ and at the same time to monitor their migration by magnetic resonance 
imaging.  
In conclusion, both aqueous and organic iron oxide colloids can be used for 
preparation of HSA-loaded submicrometer-sized magnetic PLGA particles. Magnetic 
PLGA particles might be thus promising for targeted drug delivery.  
 
Experimental  
 
Materials  
FeCl2 · 4 H2O and FeCl3 · 6 H2O were purchased from Fluka (Buchs, Switzerland), 
sodium hypochlorite solution (NaClO) from Bochemie (Bohumín, Czech Republic), 
and sodium citrate dihydrate from Lachema (Brno, Czech Republic). Poly(D,L-
lactide-co-glycolide) (50:50; Resomer® RG 502 H) was from Boehringer (Ingelheim, 
Germany), poly(vinyl alcohol) (PVA; Mw = 30,000-70,000; 89-90 % hydrolyzed) from 
Sigma-Aldrich (St. Luis, USA), human serum albumin (HSA) was from Trigon 
Biotechnological (Budapest, Hungary) and dichloromethane (DCM) was from 
Spektrum-3D (Hungary). Micro-BCA protein assay reagents were purchased from 
Pierce (Bonn, Germany). Oleic acid and other reagents were from LachNer 
(Neratovice, Czech Republic). Ultrapure Q-water ultrafiltered on a Milli-Q Gradient 
A10 system (Millipore, Molsheim, France) was used throughout the work.  
 
Synthesis of superparamagnetic citrate-stabilized γ-Fe2O3 nanoparticles dispersible 
in aqueous media  
Earlier published procedures (Macková et al. [36], Massart [37]) were modified. First, 
magnetite (Fe3O4) nanoparticles were prepared by coprecipitation from a mixture of 
FeCl2 and FeCl3 (molar ratio 1:2) upon addition of NH4OH. Briefly, 0.5 M NH4OH (80 
ml) was for 5 min added under sonication (W 385 Sonicator; Cole-Palmer 
Instruments, USA; output 40 %) to 0.2 M FeCl3 aqueous solution (80 ml), followed by 
the addition of 0.2 M FeCl2 aqueous solution (40 ml). The mixture was poured into 
0.5 M NH4OH (240 ml) under vigorous stirring (2,000 rpm) with an anchor-type stirrer 
resulting in the precipitate, which was then left standing for 30 min and washed with 
Q-water (5 times 20 ml) until peptization was achieved. 5 wt.% NaClO aqueous 
solution (10 ml) was added under sonication followed by the addition of 0.1 M sodium 
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citrate solution (13 ml) during 5 min. The resulting citrate-stabilized γ-Fe2O3 
nanoparticles were washed as above and sonicated for 5 min to achieve a 
concentration of 5 wt.%.  
 
Synthesis of superparamagnetic oleic acid-coated Fe3O4 nanoparticles dispersible in 
organic media  
Neat superparamagnetic nanoparticles were prepared by coprecipitation of FeCl2 and 
FeCl3 in aqueous ammonia solution by modification of an earlier published method 
(Horák et al. [38]). Briefly, FeCl3 · 6 H2O (24.32 g) and FeCl2 · 4 H2O (11.92 g; molar 
ratio 2:1) were stirred at 400 rpm in Q-water (50 ml) under nitrogen atmosphere. To 
this solution, 28 % NH4OH solution (50 ml; 50% excess) was added over a period of 
20–30 min. To coat the nanoparticles, oleic acid (5 ml) was added to the reaction 
mixture at 90 °C and the reaction proceeded for 5 h until the NH3 odor disappeared. 
After cooling to room temperature, the Fe3O4 nanoparticles were washed with Q-
water for 4 days (three times 200 ml a day) using separation by a magnet and 
decantation; they were then dried at 80 °C and 13 Pa to yield about 16 g of product. 
Finally, the Fe3O4 particles were under sonication resuspended in dichloromethane 
(DCM) to a concentration of 5.7 wt.%.  
 
Encapsulation of citrate-stabilized γ-Fe2O3 or oleic acid-coated Fe3O4 nanoparticles 
by PLGA  
Particles containing HSA and oleic acid-coated Fe3O4 (or citrate-stabilized γ-Fe2O3) 
were formulated by a double emulsion solvent evaporation technique.  
Briefly, aqueous solution (0.5 ml) of HSA (3.7 mg) was added to oil phase (DCM; 5 
ml) containing PLGA (200 mg) and oleic acid-coated Fe3O4 (2 mg) dispersed in DCM. 
This two-phase system was emulsified using a model W-220 probe sonicator (Heat 
Systems-Ultrasonics) for 1 min to get a water-in-oil (w/o) emulsion. The resulting 
emulsion was further homogenized in 2 wt.% PVA aqueous solution (20 ml) for 2 min 
in an ice bath to obtain w/o/w emulsion. The DCM was evaporated from w/o/w 
emulsion using magnetic stirrer (800 rpm) for 2 h. The resulting PLGA particles were 
separated by centrifugation. 
Optionally, aqueous phase (0.5 ml) containing HSA (3.7 mg) and citrate-stabilized γ-
Fe2O3 (2 mg) was added to DCM (5 ml) containing PLGA (200 mg) and the system 
was treated in the same way as described above.  
 
Characterization  
Nanoparticle size (Dn), particle size distribution (polydispersity index PDI = Dw/Dn, 
where Dw and Dn are weight- and number-average particle size, respectively) and 
morphology were determined using a Quanta S200 scanning electron microscope 
(SEM; FEI; Brno, Czech Republic)  and a Tecnai Spirit G2 transmission electron 
microscope (FEI). Hydrodynamic diameter (Dh) was measured by dynamic light 
scattering (DLS) using a Zeta-Sizer Nano ZS (Malvern Instruments; Malvern, UK). 
DLS characterizes particle size distribution by polydipersity PI typically in the range 
0-0.3, where 0 represents monodisperse particles and 0.3 their highly polydisperse 
counterparts (Koppel [39]).  
Encapsulation efficiency of HSA was determined by micro-BCA assay using a 
Pharmacia LKB Biochrom 4060 UV-VIS spectrophotometer (Cambridge, UK). In 
micro-BCA assay, peptide bonds of protein reduced cupric (Cu2+) to cuprous (Cu+) 
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ions and two molecules of bicinchonic acid chelated with each Cu+ ion forming a 
purple-colored product that strongly absorbed light at 562 nm. Content of non-
encapsulated protein was determined in the supernatant using UV-VIS spectroscopy 
and amount of encapsulated HSA calculated.  
Encapsulation efficiency of iron oxide in the sumicrometer-sized PLGA particles was 
determined after separation of non-encapsulated iron oxide from the particles. At first, 
suspension of magnetic PLGA particles in water was centrifuged at 30,000 rpm for 
30 min using a Beckman Optima Max-E ultracentrifuge (Brea, USA) to remove PVA 
solution partly stabilizing the non-encapsulated iron oxide. The magnetic PLGA 
particles were then resuspended in distilled water, whilst the aggregated iron oxide 
nanoparticles remained in the precipitate since they were not stabilized anymore. 
After removal of the supernatant, the iron oxide content was determined in the 
precipitate by a colorimetric method using Prussian Blue staining (Astete et al. [40]). 
The iron oxide was dissolved by 6 M HCl, the resulting Fe3+ solution was diluted with 
1 % HCl and reacted with equal amount of 1 % potassium ferrocyanide solution 
producing a deep blue colour. The absorbance was measured after 15 min by a UV-
VIS spectrophotometer at 700 nm. Calibration was done with a stock solution of 
iron(III) oxide powder, 99.998% of purity.   
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